NDA 020485 · Kenvue Brands
Visine
Naphazoline Hydrochloride, Pheniramine Maleate · Ophthalmic
Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Jan 31, 1996
Approved uses
2
Original approval plus efficacy supplements
Registered trials
8
4 Phase 3, 0 recruiting
FAERS reports
25
2 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 13, 2024.
Uses Temporarily relieves itchy, red eyes due to: pollen ragweed grass animal hair and dander
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 17, 2018 Supplement 13 · Efficacy LetterLabel
- Jan 31, 1996 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- VISINE · NAPHAZOLINE HYDROCHLORIDE 0.025%; PHENIRAMINE MALEATE 0.3% · SOLUTION/DROPS, OPHTHALMIC · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Naphazoline" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Pediatric Drugs in Nasal CongestionPivotal-lookingCompleted
EMSIndustry
NCT02601235 · 292 participants · Start Jan 16, 2018 · Primary completion Aug 3, 2018
Drug: Naridrin; Afrin · For: Nasal Congestion
Sites: Santo André, Brazil
- Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.Pivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00769886 · 144 participants · Start Oct 2008 · Primary completion Dec 2008
Drug: Ketotifen/naphazoline; Ketotifen and 2 more · For: Allergic Conjunctivitis
Sites: North Andover, Massachusetts
- Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.Pivotal-lookingCompleted
Bausch & Lomb IncorporatedIndustry
NCT00770133 · 141 participants · Start Feb 2010 · Primary completion Apr 2010
Drug: Ketotifen/naphazoline; Naphazoline and 2 more · For: Allergic Conjunctivitis
Sites: North Andover, Massachusetts
- Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and NasopharyngealPivotal-lookingCompleted
EMSIndustry
NCT01533220 · 132 participants · Start Jan 1, 2013 · Primary completion Aug 31, 2013
Drug: naphazoline hydrocloride; Naphazoline hydrocloride + Pheniramine Maleate + Panthenol · For: Flu; Cold; Allergic Disorder of Respiratory System
- Comparison of Tolerability Between Two Allergy DropsStatus unknown
Hom, Milton M., OD, FAAOIndividual
NCT01390961 · 48 participants (planned) · Start Aug 2011 · Primary completion Dec 2011
Drug: alacaftadine and naphazoline HCl & pheniramine maleate · For: Allergic Conjunctivitis
Sites: Azusa, California
SanofiSanofi (SNY)
NCT03324113 · 34 participants · Start Oct 17, 2017 · Primary completion Nov 18, 2022
Drug: SAR408701; dexamethasone and 2 more · For: Neoplasm Malignant
Sites: Nagoya, Japan; Kashiwa-shi, Japan; Sunto-gun, Japan
Hom, Milton M., OD, FAAOIndividual
NCT00489398 · 25 participants (planned) · Start Jul 2007
Drug: epinastine HCL and olopatadine HCL · For: Allergic Conjunctivitis
- Safety and Tolerability of PRO-185Completed
Laboratorios Sophia S.A de C.V.Industry
NCT05470868 · 22 participants · Start Feb 4, 2023 · Primary completion May 22, 2023
Drug: Naphazoline / Hypromellose Ophthalmic · For: Hyperemia Eye
Sites: Guadalajara, Mexico
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- eye irritation10
- mydriasis7
- product use in unapproved indication7
- eye pain6
- expired product administered3
- vision blurred3
- eye swelling2
- adverse event1
- drug ineffective1
- eye allergy1
- eye pruritus1
- incorrect dose administered1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2024 | 11 |
| 2025 | 9 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Prospective, randomized, controlled comparison of SYSTANE UD eye drops versus VISINE INTENSIV 1% EDO eye drops for the treatment of moderate dry eye.
Jacobi C, Kruse FE, Cursiefen C · J Ocul Pharmacol Ther 2012 · Comparative Study, Randomized Controlled Trial
- Effects of two eye drop products on computer users with subjective ocular discomfort.
Skilling FC, Weaver TA, Kato KP, et al. · Optometry 2005 · Clinical Trial, Comparative Study
- Oxymetazoline ophthalmic solution versus naphazoline solution in non-infectious conjunctivitis.
Rybiczka R, Mauracher E · Pharmatherapeutica 1983 · Clinical Trial, Comparative Study
- Ocular pain after intravitreal injection.
Sanabria MR, Montero JA, Losada MV, et al. · Curr Eye Res 2013 · Comparative Study, Randomized Controlled Trial
- Effects of ocular decongestants.
Abelson MB, Yamamoto GK, Allansmith MR · Arch Ophthalmol 1980 · Clinical Trial, Comparative Study
- Topical naphazoline in the treatment of myasthenic blepharoptosis.
Nagane Y, Utsugisawa K, Suzuki S, et al. · Muscle Nerve 2011 · Clinical Trial, Comparative Study
Sponsor: Kenvue Brands
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.